rawfin.tv
Gene-Editing Drug Shows Promise in Cholesterol Reduction Trial
TechnologytechAI Generated

Gene-Editing Drug Shows Promise in Cholesterol Reduction Trial

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

A gene-editing drug demonstrated a 62% reduction in bad cholesterol in an interim Phase I trial involving 35 participants. The early results suggest significant potential for future therapeutic applications in cardiovascular health.

biotechpharmaceuticalsgene therapymedical innovationcholesterol

Related Articles

Amazon's AI Business Reaches $25 Billion Run Rate

Amazon's AI Business Reaches $25 Billion Run Rate

tech
OpenAI Nears $30 Billion Funding Round at $1.25 Trillion Valuation

OpenAI Nears $30 Billion Funding Round at $1.25 Trillion Valuation

tech
Anthropic S-1 Filing Reveals $80.7 Billion First-Half Loss Ahead of IPO

Anthropic S-1 Filing Reveals $80.7 Billion First-Half Loss Ahead of IPO

tech
Apple Partners with Meta to Run 816-Billion AI Model Locally

Apple Partners with Meta to Run 816-Billion AI Model Locally

tech